To our best of knowledge, no GC-MS method for the analysis of prilocaine HCl in any pharmaceutical preparations was available in the literature. The development and validated an effective method for analysis of drugs in pharmaceutical preparations and biological samples for understanding the therapeutic and toxic effects of drugs is critically important. The aim of the present work is to develop and validate a new GC-MS method for determination of alone prilocaine HCl with a simple sample preparation without derivatization in pharmaceutical preparations using internal standard methodology.
EXPERIMENTALPrilocaine HCl reference substance and lidocaine HCl used as internal standard (Fig. 1-B, IS) was a kindly supplied by Novartis Pharmaceutical Industry (Ankara, Turkey) and Doping Control Center of Hacettepe University (Ankara, Turkey). The high-purity all other reagents were purchased from Merck (Germany). All gases were supplied by Havas (Ankara, Turkey)Pharmaceutical preparations: The following pharmaceutical preparations of prilocaine HCl were obtained from local sources in Erzurum (Turkey):Emla ® cream (5 % cream, Astra Zeneca A.S., Turkey) containing 25 mg prilocaine HCl, 25 mg lidocaine HCl, 55 mg poloxamer188 and 155 mg poloxomer 407.Citanest ® injection (2 % flacon, Astra Zeneca A.S., Turkey) containing prilocaine HCl 400 mg/20 mL, methyl parahydroxybenzoate and sodium chloride.